Innova Captab Limited (NSE:INNOVACAP)

Market Cap	41.84B -17.5%
Revenue (ttm)	14.97B +25.6%
Net Income	1.32B +3.9%
EPS	23.13 -8.2%
Shares Out	57.22M
PE Ratio	31.61
Forward PE	23.71
Dividend	4.00 (0.54%)
Ex-Dividend Date	Jan 30, 2026

Volume	18,193
Average Volume	41,528
Open	731.20
Previous Close	731.20
Day's Range	723.55 - 736.95
52-Week Range	622.00 - 1,020.70
Beta	-0.33
RSI	58.38
Earnings Date	May 21, 2026

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinoly...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,600
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INNOVACAP

Financial Performance

In fiscal year 2025, Innova Captab's revenue was 12.44 billion, an increase of 15.02% compared to the previous year's 10.81 billion. Earnings were 1.28 billion, an increase of 35.95%.